Tumor Genetics Research Brings Some Answers for Families at High Risk
Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Treating BRCA-Negative Pancreatic Cancer Patients with a Family Cancer History Similar to BRCA Carriers
A clinical trial looks at the effectiveness of a PARP inhibitor in BRCA-negative pancreatic cancer patients with a family history BRCA-type cancers.
New Biopsy Shows Promise For Pancreatic Cancer Patients
Trovagene is developing a liquid biopsy for pancreatic cancer patients, to allow doctors to test for cancer and track treatment response.
BRCA’s Role in Pancreatic Cancer Investigated
The relationship between BRCA and pancreatic cancer, and how that affects treatment, is the focus of clinical trials looking at PARP inhibitors.
Working with Your Doctor to Find Clinical Trials
Oncologist Kim A. Reiss explains the importance of clinical trials and family history of cancer when choosing a treatment for pancreatic cancer.
Putting the Immune System on the Offensive
A discussion of immunology in cancer treatment, focusing on the work of Elizabeth Jaffe, M.D., and her cancer vaccine and checkpoint inhibitors.
Personalized Treatment Plans in the Fight Against PC
David Dessert explains that his aunt’s genetic testing for BRCA2 mutation directed his own treatment for pancreatic cancer.